MYC and non-small cell lung carcinoma: However, limited by the high cost of chemical modification and “off target” effects of miRNA inhibitors, continuing development of small molecules, which act pharmacologically to inhibit the c-myc can be a efficient therapeutic strategy for NSCLC 45.